Full-Time

Director – Global Scientific Publications

Multiple Teams

Posted on 8/14/2025

PTC Therapeutics

PTC Therapeutics

1,001-5,000 employees

Biopharmaceuticals for rare genetic disorders

Compensation Overview

$195.5k - $246k/yr

+ Short-term Incentives + Long-term Incentives

Jackson Township, NJ, USA

Remote

East Coast candidates only.

Category
Biology & Biotech (2)
,
Requirements
  • Advance scientific degree, PharmD, PhD or MD preferred
  • 7+ years of experience in pharmaceutical/healthcare industry with a focus on scientific publications
  • Expertise across all aspects of scientific publications, including strategic planning, leading steering committee meetings, and execution during all phases of drug development and commercialization
  • In-depth knowledge of Good Publication Practices (GPP4) and other relevant industry standards (ICMJE, CONSORT, etc.), Sunshine Act, relevant Codes of Conduct (e.g. PhRMA, EFPIA), and other guidance related to post-marketing practices and scientific data communication
  • Understanding of clinical trial design and execution, statistical methods and clinical trial data reporting requirements
  • Experience in orphan products, rare disease, and products with a specialized mode of action
  • Demonstrated expertise in strategic publication planning and the development, implementation and oversight of scientific publications
  • Excellent verbal and written communication skills
  • Ability to influence without authority
  • Demonstrated experience and ability to work both independently and collaboratively in a fast-paced, matrixed environment consisting of internal and external team members
  • Excellent planning, organization and time management skills including the ability to support and prioritize multiple projects
  • Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines
  • Proficiency with PubStrat and/or other publication management tools
  • Proficiency with Zoom and other video conferencing platforms
  • Proficiency with Microsoft Teams and Microsoft Office suite
  • Fluent in English (verbal and written)
Responsibilities
  • Works closely with internal and external stakeholders in a matrix environment to develop and deliver scientific publications and related communications across all commercialized and emerging product and therapeutic areas as needed
  • When necessary, acts as liaison representing the Global Scientific Publications function at intra- and interdepartmental meetings, participating in decisions that impact the overall medical/scientific support of products within the therapeutic and asset teams
  • Strategizes and collaborates with key internal and external stakeholders to identify target publication opportunities
  • Coordinates timely and on-budget completion of publication activities with external and internal medical writers, publishing agencies and other vendors as appropriate
  • Monitors the publication requirements of and deadlines for key international/national congresses and journals
  • Defines the operational milestones of the publication plans across all therapeutic areas
  • Coordinates the review of scientific proposals and publications by the PTC Publication Steering and Review Committee members as well as PTC senior management in accordance with internal and industry-wide standard operating procedures and guidelines
  • Coordinates local abstracts and scientific publications in collaboration with local PTC affiliates and Medical Affairs colleagues
  • Submits abstracts, posters and clinical papers according to publication plan(s) and tracks the progress
  • Documents all relevant communication, reviews and approvals according to good publication practice through PubSTRAT
  • Attends scientific congresses if needed and collaborates with authors and internal colleagues on the presentation of abstracts, posters and clinical papers
  • Applies scientific and business acumen relevant to therapeutic areas, products, emerging therapies, and competitive intelligence to the objectives of scientific publication plan(s)
  • Forecasts and tracks publication costs and resources needed to support scientific publication activities
  • Manages project budgets and timelines toward timely and on-budget completion
  • Keeps internal colleagues informed of upcoming opportunities and of accepted publications
  • Facilitates training on the use of PubSTRAT for new internal colleagues and agency partners, as needed
  • Identifies, proposes and implements improvements to the scientific publication review process, systems and tools
  • Proactively identifies, and informs management of, issues that may put PTC’s products/business at risk
  • Manages agency partner performance to ensure alignment with PTC expectations
  • Provides scientific review of materials related to scientific publications as needed
  • Performs other tasks and assignments as needed and specified by manager

PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and markets medicines for rare genetic diseases. It uses RNA biology and post-transcriptional control to create therapies, including small-molecule drugs and gene therapies. Its products include Translarna for nmDMD, Evrysdi for SMA, Emflaza, Upstaza for AADC deficiency, and Kebilidi for CNS indications, all supported by an integrated model from research to commercialization and operations in more than 50 countries with a European base in Dublin. The company aims to provide safe, effective treatments to patients with few or no options by building a strong pipeline and broad global access.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South Plainfield, New Jersey

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Sephience hits $125M Q1 2026 revenue, raises 2026 guidance to $850M.
  • Votoplam slows Huntington's progression 52%, unlocks $50M Novartis milestone.
  • $1.89B cash supports global expansion to 30 countries by 2026 end.

What critics are saying

  • Emflaza generics erode DMD revenue starting 2026-2027.
  • Translarna loses Europe reimbursement as payers reject conditional status.
  • Novartis terminates PTC518 deal after INVEST-HD Phase 3 failure in 2027.

What makes PTC Therapeutics unique

  • Sephience offers dual mechanism for PKU, driving 36% Q1 2026 growth.
  • Translarna targets nonsense mutation DMD since 2014 conditional approval.
  • Upstaza delivers first brain gene therapy for AADC deficiency.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at PTC Therapeutics who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
PR Newswire
Mar 25th, 2026
PTC Therapeutics appoints biotech banking pioneer Jessica Chutter to board

PTC Therapeutics has appointed Jessica Chutter to its Board of Directors. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley after over 40 years with the firm. Chutter is considered a pioneer in biotechnology investment banking, having helped build Morgan Stanley's biotechnology banking practice. During her tenure, she was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. She holds a BA from McGill University and an MBA from Harvard University. PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing and commercialising medicines for rare disorders in children and adults. The company aims to leverage Chutter's expertise as it continues its growth trajectory.

PTC Therapeutics
Mar 4th, 2026
PTC earns Gallup's Exceptional Workplace Award for fifth year.

PTC earns Gallup's Exceptional Workplace Award for fifth year. PTC has been named a 2026 Gallup Exceptional Workplace Award winner. This is the company's fifth time earning this important recognition, and it reflects the culture PTC Therapeutics, Inc. has cultivated by enabling its people do their best work by leading with their Strengths. At PTC, PTC Therapeutics, Inc. use Gallup's CliftonStrengths to build a shared Strengths language that supports individual growth and strengthens collaboration across teams. PTC Therapeutics, Inc. encourage every employee to deepen their Strengths through coaching and ongoing conversations that turn individual strengths into meaningful impact. With this 2026 Exceptional Workplace Award, Gallup has recognized PTC for: * Strong leadership commitment to sustaining a Strengths-based culture * Deep integration of Strengths into its business and ways of working * Global One PTC approach that strengthens collaboration across teams and regions "Being recognized by Gallup for the fifth time is a powerful reflection of the consistency and care our people bring to PTC every day," said Hege Sollie-Zetlmayer, Chief Human Resources Officer. "When we lead with Strengths, we build teams that collaborate better and deliver stronger results, and that enables us to stay focused on our purpose and the patients and families we serve." PTC Therapeutics, Inc. is proud of this achievement, as it is a testament to its collective dedication to nurturing a work environment that enables employees to reach their full potential. PTC Therapeutics, Inc. celebrate this recognition with its One PTC team and continue to build upon its culture of empowerment and success. About the Gallup's 2026 Exceptional Workplace Award Gallup Exceptional Workplace Award winners change the way people work around the world. They achieve this by focusing on the engagement and Strengths of their people and investing in their development. Gallup created the Gallup Exceptional Workplace Awards to honor and recognize this commitment to developing human potential. Winners have workplace cultures that put the strengths of leaders, managers, and employees at the core of how they work every day. These achieve more by helping employees focus on what they do best, maximizing potential within teams, and integrating Strength-accelerated development into their mission, vision, and values. Learn more here.

Yahoo Finance
Mar 3rd, 2026
Palo Alto Investors adds $3M stake in PTC Therapeutics with 41,000 new shares

Palo Alto Investors LP purchased 41,303 shares of PTC Therapeutics in the fourth quarter of 2025, worth approximately $3 million, according to a 17 February 2026 SEC filing. The investment manager's stake in the biotech company increased to $68.66 million, up $15.72 million from the previous period. PTC Therapeutics now represents 9.6% of Palo Alto Investors' reportable assets under management. The biotech company, which specialises in treatments for rare diseases including Duchenne muscular dystrophy and spinal muscular atrophy, has seen its shares rise 39.9% over the past year to $69.17. The deal marks the fund's third major position in the biotechnology sector, behind Insmed and Amicus Therapeutics. PTC Therapeutics reported revenues of $806.78 million but remains unprofitable.

PharmaVoice
Oct 14th, 2025
What a gene therapy win means for the Huntington's disease pipeline

What a gene therapy win means for the Huntington's disease pipeline. Recent results for a Huntington's gene therapy confer a hopeful sign for R&D in the space. The Huntington's disease community celebrated a much-needed win last month when results for a gene therapy demonstrated slowed disease progression for the vexing neurological disorder. The phase 1/2 readout for uniQure's AMT-130 not only buoyed hopes for a disease-modifying option, but gave the larger field a boost by renewing confidence for a central hypothesis in Huntington's research: that lowering levels of a toxic protein can help keep symptoms at bay. "Beyond UniQure, the pipeline includes highly promising approaches that will ideally move the goal from merely managing symptoms to effectively controlling the disease," Amy Gray, president and CEO of the Huntington's Disease Society of America, said in an email. Huntington's research has been beset by a series of demoralizing drug failures. For a time, it appeared that uniQure's one-and-done gene therapy might join the discard pile. In 2022, the phase 1/2 trial ground to a halt when three patients in the high-dose treatment arm experienced serious neurological side effects, believed to be related to the surgical procedure that delivers the therapy deep into the most affected part of the brain. However, the three affected participants recovered and the trial continued. The uniQure gene therapy uses a viral vector to deliver a gene encoding an miRNA designed to bind to and reduce levels of the huntingtin protein, which is crucial for proper nerve function. Huntington's is linked to a mutation in the huntingtin gene, and people with the condition produce a mutated form of the protein, which creates damaging clumps in the brain that are thought to drive the disease. Unlike other treatments, such as Wave Life Sciences' WVE-003, an allele-selective antisense oligonucleotide that is now preparing to move into a registrational global trial, AMT-130 doesn't distinguish between healthy and mutant forms of the protein. Instead, it aims to reduce both. It's not yet clear if reducing levels of the healthy protein will have downstream effects. The recent uniQure trial met its primary endpoint by reducing disease progression on a standard composite scale by 75% over 30 months. Progression was compared against an external control group of similar patients from a Huntington's disease registry. "I believe these groundbreaking data are the most convincing in the field to date and underscore potential disease-modifying effects in Huntington's disease, where an urgent need persists," said Dr. Sarah Tabrizi, professor of clinical neurology, director of the University College London Huntington's Disease Centre and joint head of the department of neurodegenerative disease, in a written release. UniQure's drug is one of several Huntington's contenders that target the huntingtin protein, although their methods vary. PTC Therapeutics is developing a small-molecule drug, PTC-518, now in phase 2. It also saw some recent success, hitting its primary endpoint of reducing levels of huntingtin protein in the blood in a 12-week trial. Roche and Ionis Pharmaceuticals are continuing development for their huntingtin-lowering drug tominersen, while looking to find its niche after a phase 3 failure in 2021. The drug originally appeared to worsen symptoms with the most frequent doses, however, later analysis showed a potential benefit in a subset of younger, earlier-stage patients. A targeted trial with that group is ongoing. Where the gene therapy goes from here. Going forward, uniQure will need to prove AMT-130 can deliver results more broadly than the small group of 29 patients in its recent trial. Questions also remain about whether the disease modifying effects will be durable over time or if new safety issues might arise. Dr. Walid Abi-Saab, the chief medical officer of uniQure, said in a press release that company officials believe the drug has the potential to transform treatment for people with Huntington's, and uniQure is aiming to apply for FDA approval in the first quarter of 2026, which could lead to a launch later in the year. But scaling the drug to reach more patients will be a challenge, and like many one-time gene therapies, AMT-130 is expected to come at a high price, potentially raising affordability issues. But this is not uniQure's first gene therapy. The company gained approval in 2022 of the world's first gene therapy for hemophilia B, Hemgenix, which was commercialized by CSL Behring.

PR Newswire
Sep 2nd, 2025
RareMed Announces Expansion of Relationship with PTC Therapeutics

PITTSBURGH, Sept. 2, 2025 /PRNewswire/ - RareMed Solutions(R), the nation's leader in patient support services for complex therapies, is proud to announce an expansion of its relationship with PTC Therapeutics(TM) with the launch of non-commercial pharmacy dispensing services for PTC's therapy, Sephience(TM).

INACTIVE